GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Corcept Therapeutics CORT · USD

Health Care · US listing · 🇺🇸 United States

Compare

63.62

-2.09%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Corcept Therapeutics — daily CORT Delayed
Market value
$7.63bn
Last close × shares
Volume
1.1m
Shares, 20 Nov 2026
Price to earnings
95.4

About Corcept Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Corcept Therapeutics is based in Redwood City, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CORT. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $761.4m and net income of $99.7m. At that date it held total assets of $836.7m and shareholders' equity of $647.8m.

In its own words

We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol.

Cortisol plays a significant role in the body’s response to stress and is essential for survival. Cortisol influences metabolism and the immune system and contributes to emotional stability. Cortisol levels follow a diurnal rhythm that is essential to health, peaking upon awakening and decreasing during the day. Insufficient cortisol activity may lead to dehydration, hypotension, shock, fatigue and hypoglycemia. Excessive cortisol activity, known as hypercortisolism, may lead to hypertension, diabetes, impaired glucose tolerance, obesity, fatty liver disease, depressed mood, psychosis, wasting of the arms and legs, edema, fatigue, insomnia and other problems.

Cortisol reduces a patient’s immune response to oncogenesis, shields certain cancer cells from the apoptotic effects of chemotherapy and facilitates the growth of others. Pre-clinical and clinical data indicate that modulating cortisol activity may improve outcomes in patients with fatty liver disease and metabolic dysfunction-associated steatohepatitis (“MASH”), which are precursors of liver fibrosis and cirrhosis. Pre-clinical and clinical data also suggest that modulating cortisol activity may lead to treatments for patients with amyotrophic lateral sclerosis (“ALS”).

Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗

More about Corcept Therapeutics →

Latest on Corcept Therapeutics

Our reporting

Next results

23 Feb 2027

Due on 23 Feb 2027. Analysts expect earnings of 1.12 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Corcept Therapeutics's ticker?

Corcept Therapeutics trades as CORT on its US listing, under ISIN US2183521028.

What was Corcept Therapeutics's last closing price?

63.62 on 20 Nov 2026. The figure is in USD and is never converted.

When does Corcept Therapeutics next report results?

Results are expected on 23 Feb 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.